This data set is used to illustrate multi-state survival curves.
It is based on the actual study in the reference below.
A subset of subjects was de-identifed, reordered, and then all of the
time values randomly perturbed.
Mutations in the FLT3 domain occur in about 1/3 of AML patients,
the additional agent in treatment arm B was presumed to target this anomaly.
All subjects had a FLT mutation, either internal tandem duplications (ITD)
(divided into low vs high) +- mutations in the TKD domain, or TKD mutations
only. This was a stratification factor for treatment assignment in
the study. The levels of A, B, C correspond to increasing severity of the
mutation burden.